• After lymphatic prostheses and trato-polytics: For early breast cancer patients who are positive for human skin growth factor (HER2) positive for receptor 2 (HER2) positive, Nairatini is the I-recognition (I-1a level) for post-opaedic assisted treatment if lymphatic prosthesis is positive and has been subjected to trato-polysytics. This means that, in such cases, the use of Neiratini for intensive care is a very important and effective treatment option that further reduces the risk of relapse. • lymphopositive and lymphocyte anti-synthetic after lympholy-positive and lymphatic anti-synthetic after lymphatic anti-synthetic treatment: Nairatini is also the recommended drug for follow-up intensive sequence treatment (level II-2a). This suggests that Nairatini can also provide additional clinical benefits to patients as a means of intensive treatment after double-target treatment. 2. Supported treatment after new assistive treatment: Nairatini can be used in a sequence after chemotherapy (level III-2b) if the patient has not reached a full pathology relief (non-pCR) after the new assistive treatment. Although Naratini ‘ s referral level is relatively low in this case, Naratini can still be used as an option for additional treatment for patients who have not achieved the desired treatment. 3. Advanced rescue treatment: Naira Tini can be used as a treatment option (level III-2a) during the advanced rescue treatment, when the patient has failed to receive a single anti-treatment. This provides more treatment programmes for patients with late-term breast cancer, which helps to prolong their survival and improve their quality of life. In general, Nairatini, as an oral chesamatesterase inhibitor, has an important place in the treatment of her positive breast cancer, and has been recommended by various authorities at the international and national levels. It can significantly reduce the risk of re-emergence of Sher2-positive early breast cancer, especially for patients at high risk of relapse, where Naratini ‘ s treatment is more effective.
Breast cancer